The company will no longer develop its medicine izokibep in two immune conditions, prioritizing instead another treatment it’s developing for thyroid eye disease.
Read more about this post on BioPharmaDive
Trending
- Claret Capital Secures €575M to Support European Tech and Life Sciences Without Equity Dilution
- Elivity Launches Innovative NANOBOOST Supplement Technology in Asia
- Unlocking Patient Benefits Through Post-Approval Innovation
- Biotech Firm Set to Create 70 Jobs in Shreveport’s Kings Highway Area
- Kane Biotech Partners with OMS to Enhance Health atHome Access in Ontario
- Colorado Café Owner Stands Firm Against Health Violations and Remains Open
- Immuron Launches Gut Health Solution in the U.S. Market
- RPG Life Sciences Unveils Rs. 500 Crore Investment for API Expansion
